Aura Q3 10-Q: $297.2M Cash Into 1H 2029, Net Loss Widens to $111.4M
AURA sits 39% above its 52-week low of $4.73.
Summary
Aura's Q3 10-Q shows a $111.4M nine-month net loss and $88.8M of operating cash burn, offset by $297.2M in cash and securities that fund the company into 1H 2029, past the 2H 2027 CoMpass readout.
Key Events · Earnings and Guidance · AURA
-
Cash Runway Into 1H 2029
Cash, cash equivalents and marketable securities totaled $297.2 million at September 30, 2026, which management says funds operations into the first half of 2029 — past the expected 2H 2027 CoMpass topline.
-
Loss Widens on Phase 3 Costs
Nine-month net loss was $111.4 million versus $80.6 million a year earlier; Q3 alone lost $32.1 million as R&D rose to $24.7 million from $22.2 million on CoMpass CRO costs.
-
Restructuring Charge Booked
The August 2026 plan cutting roughly 20% of the workforce cost $4.5 million, mostly severance, and was completed in Q3; $2.7 million of the liability remained unpaid at quarter end.
-
May Offering Drove Share Count Up
Shares outstanding rose to 103,950,771 from 63,587,777 at year-end after the May 2026 follow-on sold 46,099,650 shares at $6.00 plus 3.8 million pre-funded warrants, netting $280.8 million; authorized shares were raised to 500,000,000.
Analysis · AURA · Life Sciences
The full quarterly financials behind this morning's 8-K show Aura burning $88.8M of operating cash in nine months and posting a $111.4M net loss, up from $80.6M a year ago as Phase 3 CoMpass costs and a $4.5M restructuring charge hit. Against that, $297.2M in cash and securities funds operations into the first half of 2029 — past the 2H 2027 CoMpass topline — so there is no near-term financing need and no going-concern language. The dilution already happened in May: 46.1M shares sold at $6.00 plus 3.8M pre-funded warrants, and authorized shares were raised to 500M, leaving ample room for future raises.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AURA was trading at $6.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $680.3M. The 52-week trading range was $4.73 to $9.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.